The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda

Applied Health Economics and Health Policy

Volumn 7, Issue 4, 2009, Pages 229-243

  Marseille, Elliot ^a   Kahn, James G ^b   Pitter, Christian ^c   Bunnell, Rebecca ^d   Epalatai, William ^e   Jawe, Emmanuel ^e   Were, Willy ^e   Mermin, Jonathan ^d  

^a Health Strategies International   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

^d Centers for Disease Control and Prevention Kenya   (Kenya)

^e CDC Uganda   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH ECONOMICS; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; OUTCOME ASSESSMENT; PROPHYLAXIS; RISK BENEFIT ANALYSIS; RURAL AREA; TUBERCULOSIS; UGANDA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HOME CARE SERVICES; HUMANS; MALE; QUALITY-ADJUSTED LIFE YEARS; UGANDA;

EID: 73549125240     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/bf03256157     Document Type: Article

References (62)

1. Mermin J, Were W, Ekwaru JP, et al. Mortality in HIV infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 2008; 371 (9614): 752-759
2. UNAIDS. 2006 report on the global HIV/AIDS epidemic: a UNAIDS 10th anniversary special edition. Geneva: UNAIDS, 2006
3. UNAIDS. Resource needs for an expanded response to AIDS in low and middle income countries: "making the money work". The three "ones" in action [report; discussion paper 9]. Geneva: UNAIDS, 2005 Mar
4. Kombe G, Galaty D, Gadhia R, et al. The human and financial resource requirements for scaling up HIV/AIDS services in Ethiopia [report]. Bethesda (MD): PHRplus and Abt Associates, 2005 Feb
5. Kombe G, Smith O, Nwagbara C. Scaling up antiretroviral treatment in the public sector in Nigeria: a comprehensive analysis of resource requirements [report]. Bethesda (MD): PHRplus and Abt Associates, 2004 Feb
6. Kombe G, Smith O. Application of the AIDSTREATCOST model to estimate the cost of ARV treatment in Zambia and Uganda [PowerPoint presentation]. Bethesda (MD): PHRplus, Abt Associates, and USAID, 2003 Apr 24
7. Boulle A, Kenyon C, Skordis J, et al. Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa. S Afr Med J 2002; 92 (10): 811-817
8. Govender V,McIntyre D, Grimwood A, et al. The costs and perceived quality of care for people living with HIV/AIDS in the Western Cape Province in South Africa [report]. Bethesda (MD): PHR and Abt Associates, 2000 Apr
9. Geffen N, Nattrass N, Raubenheimer C. The cost of HIV prevention and treatment interventions in South Africa [CSRR working paper #28]. Cape Town: Center for Social Science Research, AIDS and Society Research Unit, University of Cape Town, 2003 Jan
10. Cleary S, Jikwana S, Boulle A. Resource requirements for comprehensive HIV and AIDS Care, management and treatment in South Africa: March 2004-March 2009 South African Health Review 2005. Durban: South African Health Systems Trust, 2004
11. Hogan DR, Baltussen R, Hayashi C, et al. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ 2005; 331: 1431-1437
12. Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 2005; 3 (1): e4
13. Cleary S, Boulle A, McIntyre D, et al. Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township. Cape Town: Médecins Sans Frontiè res, Health Systems Trust, University of Capetown, 2004 March
14. Goldie SJ,Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Côte d'Ivoire. N Engl J Med 2006; 355 (11): 1141-1153
15. Uganda Bureau of Statistics, Macro International. Uganda demographic and health survey 2006. Calverton (MD), 2001: 500
16. UNAIDS. 2008 report on the global HIV/AIDS epidemic. Geneva: UNAIDS, 2008: 236
17. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults in resource-limited settings: recommendations for a public health approach. Geneva: WHO, 2006
18. Weidle PJ, Wamai N, Solberg P, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006; 368 (9547): 1587-1594
19. World Bank. World development report 1993: investing in health. New York: Oxford University Press, 1993
20. Mathers CD, Bernard C, Iburg KM, et al. Global burden of disease in 2002: data sources, methods and results (revised) [Global Programme on Evidence for Health Policy discussion paper no. 54]. Geneva: WHO, 2004
21. Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. 2nd ed. New York: Oxford University Press, 2006
22. Expenditure reports. Entebbe: Centers for Disease Control and Prevention, Global AIDS Program, 2004. (Data on file)
23. Médecins Sans Frontiè res. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. 10th ed. Geneva: Médecins Sans Frontiè res, 2007
24. Time and motion data. Entebbe: Centers for Disease Control and Prevention, Global AIDS Program, 2005 Aug. (Data on file)
25. Nombela N, Kouadio B, Toure S, et al. Nonantiretroviral drug consumption by CD4 cell count in HIV-infected adults: a 5-year cohort study in Côte d'Ivoire. J Acquir Immune Defic Syndr 2006; 41 (2): 225-231
26. HBAC Program weekly home-visit records. Entebbe: Centers for Disease Control and Prevention, Global AIDS Program, 2004. (Data on file)
27. Pitter C, Kahn JG, Marseille E, et al. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda. J Acquir ImmuneDefic Syndr 2007; 44 (3): 336-343
28. Morgan D, Malamba SS, Maude GH, et al. An HIV-1 natural history cohort and survival times in rural Uganda. AIDS 1997; 11 (5): 633-640
29. Marseille E, Saba J, Muyingo S, et al. The costs and benefits of private sector provision of treatment to HIV-infected employees inKampala, Uganda. AIDS 2006; 20 (6): 907-914
30. Mermin J.Mortality rates forHIV-negative children (10yrs). 2006; Jan 25 (Data on file)
31. Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 1994; 72: 429-445
32. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. Aids 2007; 21: 713-719
33. Mermin J, Ekwaru JP, Liechty CA, et al. Effect of cotrimoxazole prophylaxis, antiretroviral therapy, and insecticide- treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367: 1256-1261
34. Mermin J, Lule JR, Ekwaru JP. Association between malaria and CD4 cell count decline among persons with HIV. J Acquir Immune Defic Syndr 2006; 41 (1): 129-130 (Pubitemid 41786034)
35. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20 (1): 85-92
36. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission ofHIV- 1: a randomized clinical trial. JAMA 2000; 283 (9): 1167-1174
37. Palombi L, Germano P, Liotta G, et al. DREAM program: 6-month follow-up of the prevention of mother-to-child transmission service [abstract no. 723]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-8; Denver (CO)
38. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Medical Publications, 1997
39. Médecins Sans Frontières. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. 10th ed. Geneva: Médecins Sans Frontiè res, 2007 Jul
40. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Geneva: WHO, 2007
41. Médecins Sans Frontières. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. 8th ed.Geneva:Médecins Sans Frontières, 2005
42. McFadyen J. International drug price indicator guide. Cambridge: Management Sciences for Health, 2005
43. Palombi L, Germano P, Liotta G, et al. The DREAM cohort: antiretroviral treatment for PMTCT. HAART in pregnancy: safety, effectiveness, and protection from viral resistance. Results from the DREAM cohort [abstract no. 67]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston (MA)
44. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18 (6): 887-895
45. Mbori-Ngacha D, Nduati R, John G, et al. Morbidity and mortality in breastfed and formula-fed infants of HIV-1- infected women: a randomized clinical trial. JAMA 2001; 286 (19): 2413-2420
46. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362 (9387): 859-868
47. Dukers NH, Goudsmit J, de Wit JB, et al. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS 2001; 15 (3): 369-378
48. Gray RH, Li X, Wawer MJ, et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS 2003; 17 (13): 1941-1951
49. Over M, Marseille E, Sudhakar K, et al. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options. Sex Transm Dis 2006; 33 (10 Suppl.): S145-52
50. Morgan MG, Henrion M. Uncertainty: a guide to dealing with uncertainty in quantitative risk and policy analysis. Cambridge: Cambridge University Press, 1990
51. New agreements to lower prices of HIV/AIDS rapid tests and second-line drug [press release; online]. Available from URL: http://www.clintonfoundation. org/011206-nr-cf-hs-ai-isr-indchn- zaf-bra-pr-new-agreements-to-lower-prices-of- hiv-aidsrapid- tests-and-second-line-drugs.htm [Accessed 2006 May 19]
52. Marseille E, Dandona L, Saba J, et al. Assessing the efficiency of HIV prevention around theworld: methods of thePANCEA project. Health Serv Res 2004; 39 (6 Pt 2): 1993-2012
53. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92 (3): 388-394
54. Page-Shafer KA, McFarlandW, Kohn R, et al. Increases in unsafe sex and rectal gonorrhea among men who have sex with men: San Francisco, California, 1994-1997. MMWR Morb Mortal Wkly Rep 1999; 48 (3): 45-48
55. Dodds JP, Nardone A, Mercey DE, et al. Increase in high risk sexual behaviour among homosexual men, London 1996-8: cross sectional, questionnaire study. Br Med J (Clin Res Ed) 2000; 320 (7248): 1510-1511
56. Kalichman SC, Nachimson D, Cherry C, et al. AIDS treatment advances and behavioral prevention setbacks: preliminary assessment of reduced perceived threat of HIV-AIDS. Health Psychol 1998; 17 (6): 546-550
57. Over M, Heywood P, Gold J, et al. HIV/AIDS treatment and prevention in India: modeling the costs and consequences. Washington, DC: The World Bank, 2004
58. Samb B, Celletti F, Holloway J, et al. Rapid expansion of the health workforce in response to the HIV epidemic. N Engl J Med 2007; 357 (24): 2510-2514
59. Over M, Heywood P, Gold J, et al. HIV prevention and treatment in India: modeling the costs and consequences. Washington, DC: The World Bank, 2004
60. Creese A, Floyd K, Alban A, et al. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002; 359 (9318): 1635-1643
61. Bell JC, Rose DN, Sacks HS. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is costeffective. AIDS 1999; 13 (12): 1549-1556
62. Kahn JG, Marseille E, Auvert B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med 2006; 3 (12): e517